fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Risedronate sodium

20 general benefit · 3 not a benefit

Teva-Risedronate · DIN 02298376 · 5 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Teva-Risedronate · DIN 02298376 Manufacturer: Teva Canada Limited; listing date 2010-04-23 Health Canada: Marketed since 2011-06-03 · brand TEVA-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM MONOHYDRATE) 5 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Risedronate: Formulary list price $1.84 per unit (the source does not state the unit; exact figure $1.8445). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02298376)

Source record
DIN 02298376: Teva-Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000372; group id 954; item number 2263; lccId None; manufacturer id TEV Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.8445; ministry $1.8445 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02298376 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78367
Interchangeable products
Actonel · DIN 02242518 · not recorded
Shortage status: resolved shortage (ended June 3, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02298376
Shortage record checked October 6, 2026

Teva-Risedronate · DIN 02298384 · 30 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Teva-Risedronate · DIN 02298384 Manufacturer: Teva Canada Limited; listing date 2010-04-23 Health Canada: Marketed since 2011-06-03 · brand TEVA-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM MONOHYDRATE) 30 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Risedronate: Formulary list price $11.38 per unit (the source does not state the unit; exact figure $11.3807). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02298384)

Source record
DIN 02298384: Teva-Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000340; group id 954; item number 2264; lccId None; manufacturer id TEV Source form: Tab; strength: 30mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $11.3807; ministry $11.3807 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02298384 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78368
Interchangeable products
Actonel · DIN 02239146 · not recorded
Shortage status: discontinued (April 7, 2025, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02298384
Shortage record checked October 6, 2026

AA-Risedronate DR · DIN 02493268 · 35 mg · DR tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
AA-Risedronate DR · DIN 02493268 Manufacturer: A A Pharma Inc.; listing date 2021-07-30 Health Canada: Marketed since 2023-09-08 · brand AA-RISEDRONATE DR · ATC M05BA07 RISEDRONIC ACID · form Tablet (delayed-release) · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35 MG · company Aa pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

AA-Risedronate DR: Formulary list price $2.97 per unit (the source does not state the unit; exact figure $2.9663). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02493268)

Source record
DIN 02493268: AA-Risedronate DR Raw flags: chronicUseMed=Y, sec3=Y Item: 920000656; group id 954; item number 2262; lccId None; manufacturer id AAP Source form: DR Tab; strength: 35mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $2.9663; ministry $2.9663 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02493268 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98324
Interchangeable products
Actonel DR · DIN 02370417 · $2.9663
Shortage status: resolved shortage (ended March 11, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02493268
Shortage record checked October 6, 2026

Actonel DR · DIN 02370417 · 35 mg · DR tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Savings card: RxHelp ONE lists Actonel DR (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Actonel DR · DIN 02370417 Manufacturer: Warner Chilcott Canada Co.; listing date 2012-02-29 Health Canada: Marketed since 2025-05-22 · brand ACTONEL DR · ATC M05BA07 RISEDRONIC ACID · form Tablet (delayed-release) · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35 MG · company Abbvie corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02370417)

Source record
DIN 02370417: Actonel DR Raw flags: chronicUseMed=Y, sec3=Y Item: 920000656; group id 954; item number 2262; lccId None; manufacturer id WAR Source form: DR Tab; strength: 35mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $11.8653; ministry $2.9663 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02370417 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85557
Interchangeable products
AA-Risedronate DR · DIN 02493268 · $2.9663
Shortage status: resolved shortage (ended June 18, 2020); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02370417
Shortage record checked October 6, 2026

Apo-Risedronate · DIN 02353687 · 35 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Apo-Risedronate · DIN 02353687 Manufacturer: Apotex Inc.; listing date 2010-10-28 Health Canada: Marketed since 2012-06-20 · brand APO-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Risedronate: Formulary list price $1.68 per unit (the source does not state the unit; exact figure $1.6764). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02353687)

Source record
DIN 02353687: Apo-Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000430; group id 954; item number 2265; lccId None; manufacturer id APX Source form: Tab; strength: 35mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.6764; ministry $1.6764 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02353687 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83888
Interchangeable products
Actonel · DIN 02246896 · not recorded Auro-Risedronate · DIN 02406306 · $1.6764 Jamp-Risedronate · DIN 02368552 · $1.6764 PMS-Risedronate · DIN 02302209 · $1.6764 Ratio-Risedronate · DIN 02319861 · $1.6764 Risedronate · DIN 02370255 · $1.6764 Risedronate · DIN 02411407 · $1.6764 Riva-Risedronate · DIN 02341077 · $1.6764 Sandoz Risedronate · DIN 02327295 · $1.6764 Teva-Risedronate · DIN 02298392 · $1.6764
Shortage status: resolved shortage (ended December 20, 2018); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02353687
Shortage record checked October 6, 2026

Auro-Risedronate · DIN 02406306 · 35 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Auro-Risedronate · DIN 02406306 Manufacturer: Auro Pharma Inc.; listing date 2013-09-27 Health Canada: Marketed since 2013-07-08 · brand AURO-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Auro-Risedronate: Formulary list price $1.68 per unit (the source does not state the unit; exact figure $1.6764). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02406306)

Source record
DIN 02406306: Auro-Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000430; group id 954; item number 2265; lccId None; manufacturer id AUR Source form: Tab; strength: 35mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.6764; ministry $1.6764 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02406306 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89102
Interchangeable products
Actonel · DIN 02246896 · not recorded Apo-Risedronate · DIN 02353687 · $1.6764 Jamp-Risedronate · DIN 02368552 · $1.6764 PMS-Risedronate · DIN 02302209 · $1.6764 Ratio-Risedronate · DIN 02319861 · $1.6764 Risedronate · DIN 02370255 · $1.6764 Risedronate · DIN 02411407 · $1.6764 Riva-Risedronate · DIN 02341077 · $1.6764 Sandoz Risedronate · DIN 02327295 · $1.6764 Teva-Risedronate · DIN 02298392 · $1.6764
Shortage status: resolved shortage (ended November 28, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02406306
Shortage record checked October 6, 2026

PMS-Risedronate · DIN 02302209 · 35 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
PMS-Risedronate · DIN 02302209 Manufacturer: Pharmascience Inc.; listing date 2010-10-28 Health Canada: Marketed since 2010-07-27 · brand PMS-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Risedronate: Formulary list price $1.68 per unit (the source does not state the unit; exact figure $1.6764). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02302209)

Source record
DIN 02302209: PMS-Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000430; group id 954; item number 2265; lccId None; manufacturer id PMS Source form: Tab; strength: 35mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.6764; ministry $1.6764 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02302209 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78754
Interchangeable products
Actonel · DIN 02246896 · not recorded Apo-Risedronate · DIN 02353687 · $1.6764 Auro-Risedronate · DIN 02406306 · $1.6764 Jamp-Risedronate · DIN 02368552 · $1.6764 Ratio-Risedronate · DIN 02319861 · $1.6764 Risedronate · DIN 02370255 · $1.6764 Risedronate · DIN 02411407 · $1.6764 Riva-Risedronate · DIN 02341077 · $1.6764 Sandoz Risedronate · DIN 02327295 · $1.6764 Teva-Risedronate · DIN 02298392 · $1.6764
Shortage status: resolved shortage (ended August 2, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02302209
Shortage record checked October 6, 2026

Risedronate · DIN 02370255 · 35 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Risedronate · DIN 02370255 Manufacturer: Sanis Health Inc.; listing date 2020-06-30 Health Canada: Marketed since 2025-02-13 · brand RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Risedronate: Formulary list price $1.68 per unit (the source does not state the unit; exact figure $1.6764). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02370255)

Source record
DIN 02370255: Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000430; group id 954; item number 2265; lccId None; manufacturer id SAI Source form: Tab; strength: 35mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.6764; ministry $1.6764 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02370255 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85541
Interchangeable products
Actonel · DIN 02246896 · not recorded Apo-Risedronate · DIN 02353687 · $1.6764 Auro-Risedronate · DIN 02406306 · $1.6764 Jamp-Risedronate · DIN 02368552 · $1.6764 PMS-Risedronate · DIN 02302209 · $1.6764 Ratio-Risedronate · DIN 02319861 · $1.6764 Risedronate · DIN 02411407 · $1.6764 Riva-Risedronate · DIN 02341077 · $1.6764 Sandoz Risedronate · DIN 02327295 · $1.6764 Teva-Risedronate · DIN 02298392 · $1.6764
Shortage status: resolved shortage (ended March 25, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02370255
Shortage record checked October 6, 2026

Risedronate · DIN 02411407 · 35 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Risedronate · DIN 02411407 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-05-29 Health Canada: Marketed since 2024-02-01 · brand RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM MONOHYDRATE) 35 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Risedronate: Formulary list price $1.68 per unit (the source does not state the unit; exact figure $1.6764). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02411407)

Source record
DIN 02411407: Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000430; group id 954; item number 2265; lccId None; manufacturer id SIV Source form: Tab; strength: 35mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.6764; ministry $1.6764 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02411407 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89602
Interchangeable products
Actonel · DIN 02246896 · not recorded Apo-Risedronate · DIN 02353687 · $1.6764 Auro-Risedronate · DIN 02406306 · $1.6764 Jamp-Risedronate · DIN 02368552 · $1.6764 PMS-Risedronate · DIN 02302209 · $1.6764 Ratio-Risedronate · DIN 02319861 · $1.6764 Risedronate · DIN 02370255 · $1.6764 Riva-Risedronate · DIN 02341077 · $1.6764 Sandoz Risedronate · DIN 02327295 · $1.6764 Teva-Risedronate · DIN 02298392 · $1.6764
Shortage status: resolved shortage (ended February 16, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02411407
Shortage record checked October 6, 2026

Riva-Risedronate · DIN 02341077 · 35 mg · tablet

General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Riva-Risedronate · DIN 02341077 Manufacturer: Laboratoire Riva Inc.; listing date 2021-08-31 Health Canada: Marketed since 2010-07-28 · brand RIVA-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35 MG · company Laboratoire riva inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Riva-Risedronate: Formulary list price $1.68 per unit (the source does not state the unit; exact figure $1.6764). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02341077)

Source record
DIN 02341077: Riva-Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000430; group id 954; item number 2265; lccId None; manufacturer id RIA Source form: Tab; strength: 35mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.6764; ministry $1.6764 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02341077 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82662
Interchangeable products
Actonel · DIN 02246896 · not recorded Apo-Risedronate · DIN 02353687 · $1.6764 Auro-Risedronate · DIN 02406306 · $1.6764 Jamp-Risedronate · DIN 02368552 · $1.6764 PMS-Risedronate · DIN 02302209 · $1.6764 Ratio-Risedronate · DIN 02319861 · $1.6764 Risedronate · DIN 02370255 · $1.6764 Risedronate · DIN 02411407 · $1.6764 Sandoz Risedronate · DIN 02327295 · $1.6764 Teva-Risedronate · DIN 02298392 · $1.6764
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02341077
Shortage record checked October 6, 2026

Sandoz Risedronate · DIN 02327295 · 35 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Sandoz Risedronate · DIN 02327295 Manufacturer: Sandoz Canada Inc.; listing date 2010-10-28 Health Canada: Marketed since 2010-07-28 · brand SANDOZ RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sandoz Risedronate: Formulary list price $1.68 per unit (the source does not state the unit; exact figure $1.6764). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02327295)

Source record
DIN 02327295: Sandoz Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000430; group id 954; item number 2265; lccId None; manufacturer id SDZ Source form: Tab; strength: 35mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.6764; ministry $1.6764 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02327295 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81259
Interchangeable products
Actonel · DIN 02246896 · not recorded Apo-Risedronate · DIN 02353687 · $1.6764 Auro-Risedronate · DIN 02406306 · $1.6764 Jamp-Risedronate · DIN 02368552 · $1.6764 PMS-Risedronate · DIN 02302209 · $1.6764 Ratio-Risedronate · DIN 02319861 · $1.6764 Risedronate · DIN 02370255 · $1.6764 Risedronate · DIN 02411407 · $1.6764 Riva-Risedronate · DIN 02341077 · $1.6764 Teva-Risedronate · DIN 02298392 · $1.6764
Shortage status: resolved shortage (ended March 11, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02327295
Shortage record checked October 6, 2026

Teva-Risedronate · DIN 02298392 · 35 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Teva-Risedronate · DIN 02298392 Manufacturer: Teva Canada Limited; listing date 2010-04-23 Health Canada: Marketed since 2011-06-03 · brand TEVA-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM MONOHYDRATE) 35 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Risedronate: Formulary list price $1.68 per unit (the source does not state the unit; exact figure $1.6764). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02298392)

Source record
DIN 02298392: Teva-Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000430; group id 954; item number 2265; lccId None; manufacturer id TEV Source form: Tab; strength: 35mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.6764; ministry $1.6764 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02298392 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78369
Interchangeable products
Actonel · DIN 02246896 · not recorded Apo-Risedronate · DIN 02353687 · $1.6764 Auro-Risedronate · DIN 02406306 · $1.6764 Jamp-Risedronate · DIN 02368552 · $1.6764 PMS-Risedronate · DIN 02302209 · $1.6764 Ratio-Risedronate · DIN 02319861 · $1.6764 Risedronate · DIN 02370255 · $1.6764 Risedronate · DIN 02411407 · $1.6764 Riva-Risedronate · DIN 02341077 · $1.6764 Sandoz Risedronate · DIN 02327295 · $1.6764
Shortage status: resolved shortage (ended February 5, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02298392
Shortage record checked October 6, 2026

Actonel · DIN 02316838 · 150 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Actonel · DIN 02316838 Manufacturer: Warner Chilcott Canada Co.; listing date 2009-06-23 Health Canada: Marketed since 2025-05-05 · brand ACTONEL · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 150 MG · company Abbvie corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02316838)

Source record
DIN 02316838: Actonel Raw flags: chronicUseMed=Y, sec3=Y Item: 920000595; group id 954; item number 2266; lccId None; manufacturer id WAR Source form: Tab; strength: 150mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $47.3370; ministry $11.1875 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02316838 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80233
Interchangeable products
Apo-Risedronate · DIN 02377721 · $11.1875 Auro-Risedronate · DIN 02442760 · $11.1875 PMS-Risedronate · DIN 02424177 · $11.1875 Risedronate · DIN 02528460 · $11.1875 Teva-Risedronate · DIN 02413809 · $11.1875
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02316838
Shortage record checked October 6, 2026

Apo-Risedronate · DIN 02377721 · 150 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Risedronate · DIN 02377721 Manufacturer: Apotex Inc.; listing date 2012-06-26 Health Canada: Marketed since 2012-05-17 · brand APO-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 150 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Risedronate: Formulary list price $11.19 per unit (the source does not state the unit; exact figure $11.1875). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02377721)

Source record
DIN 02377721: Apo-Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000595; group id 954; item number 2266; lccId None; manufacturer id APX Source form: Tab; strength: 150mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $11.1875; ministry $11.1875 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02377721 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86354
Interchangeable products
Actonel · DIN 02316838 · $11.1875 Auro-Risedronate · DIN 02442760 · $11.1875 PMS-Risedronate · DIN 02424177 · $11.1875 Risedronate · DIN 02528460 · $11.1875 Teva-Risedronate · DIN 02413809 · $11.1875
Shortage status: resolved shortage (ended March 4, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02377721
Shortage record checked October 6, 2026

PMS-Risedronate · DIN 02424177 · 150 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Risedronate · DIN 02424177 Manufacturer: Pharmascience Inc.; listing date 2014-07-30 Health Canada: Marketed since 2014-05-28 · brand PMS-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 150 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Risedronate: Formulary list price $11.19 per unit (the source does not state the unit; exact figure $11.1875). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02424177)

Source record
DIN 02424177: PMS-Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000595; group id 954; item number 2266; lccId None; manufacturer id PMS Source form: Tab; strength: 150mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $11.1875; ministry $11.1875 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02424177 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90889
Interchangeable products
Actonel · DIN 02316838 · $11.1875 Apo-Risedronate · DIN 02377721 · $11.1875 Auro-Risedronate · DIN 02442760 · $11.1875 Risedronate · DIN 02528460 · $11.1875 Teva-Risedronate · DIN 02413809 · $11.1875
Shortage status: resolved shortage (ended March 9, 2020); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02424177
Shortage record checked October 6, 2026

Risedronate · DIN 02528460 · 150 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Risedronate · DIN 02528460 Manufacturer: Sanis Health Inc.; listing date 2022-11-30 Health Canada: Marketed since 2022-10-05 · brand RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 150 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Risedronate: Formulary list price $11.19 per unit (the source does not state the unit; exact figure $11.1875). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02528460)

Source record
DIN 02528460: Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000595; group id 954; item number 2266; lccId None; manufacturer id SAI Source form: Tab; strength: 150mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $11.1875; ministry $11.1875 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02528460 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101771
Interchangeable products
Actonel · DIN 02316838 · $11.1875 Apo-Risedronate · DIN 02377721 · $11.1875 Auro-Risedronate · DIN 02442760 · $11.1875 PMS-Risedronate · DIN 02424177 · $11.1875 Teva-Risedronate · DIN 02413809 · $11.1875
Shortage status: resolved shortage (ended April 28, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02528460
Shortage record checked October 6, 2026

Teva-Risedronate · DIN 02413809 · 150 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Risedronate · DIN 02413809 Manufacturer: Teva Canada Limited; listing date 2014-01-03 Health Canada: Marketed since 2013-10-10 · brand TEVA-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM MONOHYDRATE) 150 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Risedronate: Formulary list price $11.19 per unit (the source does not state the unit; exact figure $11.1875). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02413809)

Source record
DIN 02413809: Teva-Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000595; group id 954; item number 2266; lccId None; manufacturer id TEV Source form: Tab; strength: 150mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $11.1875; ministry $11.1875 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02413809 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89845
Interchangeable products
Actonel · DIN 02316838 · $11.1875 Apo-Risedronate · DIN 02377721 · $11.1875 Auro-Risedronate · DIN 02442760 · $11.1875 PMS-Risedronate · DIN 02424177 · $11.1875 Risedronate · DIN 02528460 · $11.1875
Shortage status: resolved shortage (ended June 16, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02413809
Shortage record checked October 6, 2026

Actonel · DIN 02246896 · 35 mg · tablet

Listed, not a benefitMarketed · checked October 5, 2026
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Actonel · DIN 02246896 Manufacturer: Warner Chilcott Canada Co.; listing date 2003-04-16 Health Canada: Marketed since 2025-03-05 · brand ACTONEL · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35 MG · company Abbvie corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Actonel: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02246896)

Source record
DIN 02246896: Actonel Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 920000430; group id 954; item number 2265; lccId None; manufacturer id WAR Source form: Tab; strength: 35mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02246896 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71123
Interchangeable products
Apo-Risedronate · DIN 02353687 · $1.6764 Auro-Risedronate · DIN 02406306 · $1.6764 Jamp-Risedronate · DIN 02368552 · $1.6764 PMS-Risedronate · DIN 02302209 · $1.6764 Ratio-Risedronate · DIN 02319861 · $1.6764 Risedronate · DIN 02370255 · $1.6764 Risedronate · DIN 02411407 · $1.6764 Riva-Risedronate · DIN 02341077 · $1.6764 Sandoz Risedronate · DIN 02327295 · $1.6764 Teva-Risedronate · DIN 02298392 · $1.6764
Shortage status: resolved shortage (ended October 11, 2019); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02246896
Shortage record checked October 6, 2026

Auro-Risedronate · DIN 02442760 · 150 mg · tablet

General benefitDormant since July 24, 2020 · checked October 5, 2026 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Risedronate · DIN 02442760 Manufacturer: Auro Pharma Inc.; listing date 2018-04-30 Health Canada: Dormant since 2020-07-24 · brand AURO-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 150 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Auro-Risedronate: Formulary list price $11.19 per unit (the source does not state the unit; exact figure $11.1875). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02442760)

Source record
DIN 02442760: Auro-Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000595; group id 954; item number 2266; lccId None; manufacturer id AUR Source form: Tab; strength: 150mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $11.1875; ministry $11.1875 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02442760 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92715
Interchangeable products
Actonel · DIN 02316838 · $11.1875 Apo-Risedronate · DIN 02377721 · $11.1875 PMS-Risedronate · DIN 02424177 · $11.1875 Risedronate · DIN 02528460 · $11.1875 Teva-Risedronate · DIN 02413809 · $11.1875
Shortage status: active shortage (reported March 5, 2019, last updated March 6, 2019) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02442760
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since July 24, 2020 — choose a marketed DIN from the same-category list.

Jamp-Risedronate · DIN 02368552 · 35 mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2022-09-06 — choose a marketed DIN from the same-category list.Discontinued September 6, 2022 · checked November 17, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-09-06 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-09-06 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Jamp-Risedronate · DIN 02368552 Manufacturer: Jamp Pharma Corporation; listing date 2012-08-27 Health Canada: Cancelled post market since 2022-09-06 · brand JAMP-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp-Risedronate: Formulary list price $1.68 per unit (the source does not state the unit; exact figure $1.6764). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02368552)

Source record
DIN 02368552: Jamp-Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000430; group id 954; item number 2265; lccId None; manufacturer id JPC Source form: Tab; strength: 35mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.6764; ministry $1.6764 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02368552 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85353
Interchangeable products
Actonel · DIN 02246896 · not recorded Apo-Risedronate · DIN 02353687 · $1.6764 Auro-Risedronate · DIN 02406306 · $1.6764 PMS-Risedronate · DIN 02302209 · $1.6764 Ratio-Risedronate · DIN 02319861 · $1.6764 Risedronate · DIN 02370255 · $1.6764 Risedronate · DIN 02411407 · $1.6764 Riva-Risedronate · DIN 02341077 · $1.6764 Sandoz Risedronate · DIN 02327295 · $1.6764 Teva-Risedronate · DIN 02298392 · $1.6764
Shortage status: active shortage (reported November 1, 2019, estimated to end December 30, 2022, last updated April 7, 2021) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02368552
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since September 6, 2022 — choose a marketed DIN from the same-category list.

Ratio-Risedronate · DIN 02319861 · 35 mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2015-10-26 — choose a marketed DIN from the same-category list.Discontinued October 26, 2015 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2015-10-26 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2015-10-26 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Ratio-Risedronate · DIN 02319861 Manufacturer: Ratiopharm Inc.; listing date 2010-10-28 Health Canada: Cancelled post market since 2015-10-26 · brand RATIO-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35 MG · company Ratiopharm inc division of teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ratio-Risedronate: Formulary list price $1.68 per unit (the source does not state the unit; exact figure $1.6764). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02319861)

Source record
DIN 02319861: Ratio-Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000430; group id 954; item number 2265; lccId None; manufacturer id RPH Source form: Tab; strength: 35mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.6764; ministry $1.6764 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02319861 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80533
Interchangeable products
Actonel · DIN 02246896 · not recorded Apo-Risedronate · DIN 02353687 · $1.6764 Auro-Risedronate · DIN 02406306 · $1.6764 Jamp-Risedronate · DIN 02368552 · $1.6764 PMS-Risedronate · DIN 02302209 · $1.6764 Risedronate · DIN 02370255 · $1.6764 Risedronate · DIN 02411407 · $1.6764 Riva-Risedronate · DIN 02341077 · $1.6764 Sandoz Risedronate · DIN 02327295 · $1.6764 Teva-Risedronate · DIN 02298392 · $1.6764
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02319861
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since October 26, 2015 — choose a marketed DIN from the same-category list.

Actonel · DIN 02242518 · 5 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2019-01-04 — choose a marketed DIN from the same-category list.Discontinued January 4, 2019 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2019-01-04 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2019-01-04 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Actonel · DIN 02242518 Manufacturer: Warner Chilcott Canada Co.; listing date 2001-03-07 Health Canada: Cancelled post market since 2019-01-04 · brand ACTONEL · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 5 MG · company Allergan pharma co. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Actonel: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02242518)

Source record
DIN 02242518: Actonel Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 920000372; group id 954; item number 2263; lccId None; manufacturer id WAR Source form: Tab; strength: 5mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02242518 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66266
Interchangeable products
Teva-Risedronate · DIN 02298376 · $1.8445
Shortage status: active shortage (reported not recorded, last updated December 20, 2018) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242518
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since January 4, 2019 — choose a marketed DIN from the same-category list.

Actonel · DIN 02239146 · 30 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2019-01-04 — choose a marketed DIN from the same-category list.Discontinued January 4, 2019 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2019-01-04 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2019-01-04 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Actonel · DIN 02239146 Manufacturer: Warner Chilcott Canada Co.; listing date 2000-04-17 Health Canada: Cancelled post market since 2019-01-04 · brand ACTONEL · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 30 MG · company Allergan pharma co. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Actonel: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02239146)

Source record
DIN 02239146: Actonel Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 920000340; group id 954; item number 2264; lccId None; manufacturer id WAR Source form: Tab; strength: 30mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02239146 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62602
Interchangeable products
Teva-Risedronate · DIN 02298384 · $11.3807
Shortage status: discontinued (January 20, 2017, reported by ALLERGAN PHARMA CO.); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02239146
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since January 4, 2019 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (M05B, M05BA): coverage varies; not interchangeable

  • Alendronate (Fosamax): general benefit, not a benefit
  • Clodronate (Ostac): limited Use 280, 358, 359, not a benefit
  • Etidronate (Didronel): limited Use 236, 237, not a benefit
  • Zoledronic acid (Aclasta): limited Use 319, 436, 523, not a benefit
  • Pamidronate (Aredia): not a benefit
  • Alendronate + cholecalciferol (Fosavance): general benefit

1 more in the class list below

Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM, RISPERIDONE Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

CLODRONATE DISODIUM

· 2 products · Listed, not a benefit (1), Limited Use, codes 280, 358, 359 (1) · strengths: 400mg · Cap

ETIDRONATE DISODIUM

· 2 products · Listed, not a benefit (1), Limited Use, codes 236, 237 (1) · strengths: 200mg · Tab

ZOLEDRONIC ACID

· 12 products · Limited Use, codes 319, 436, 523 (2), Off-Formulary Interchangeable, not an ODB benefit (9), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 5mg/100mL, 4mg/5mL · Inj Sol-100mL Pk (Preservative-Free), Inj Sol-5mL Pk (Preservative-Free)

PAMIDRONATE DISODIUM

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 3mg/mL, 6mg/mL, 9mg/mL · Inj Sol-10mL Vial

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

DENOSUMAB

· 8 products · Limited Use, codes 687, 688 (4), Limited Use, codes 686 (4) · strengths: 60mg/mL, 120mg/1.7mL · Inj Sol-1.0mL Pref Syr Pk (Preservative-Free), Inj Sol-Pref Syr, Inj Sol-Pref Syr (Preservative-Free), Inj Sol-Vial Pk, Inj Sol-Vial Pk (Preservative-Free)

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:00 and 78 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: osteoporosis in men, osteoporosis in postmenopausal women
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL ALENDRONATE & CHOLECALCIFEROL · General benefit 1 INDICATIONS FOSAVANCE® (alendronate sodium/cholecalciferol) is indicated for: • The treatment of osteoporosis in postmenopausal women. PM: https://pdf.hres.ca/dpd_pm/00071923.PDF; date not captured; DIN 02276429; fetched 2026-09-10 Product monograph • The treatment of osteoporosis in men. PM: https://pdf.hres.ca/dpd_pm/00071923.PDF; date not captured; DIN 02276429; fetched 2026-09-10 Product monograph RALOXIFENE HCL · Limited Use, codes 373 INDICATIONS AND CLINICAL USE APO-RALOXIFENE (raloxifene hydrochloride) is indicated for the treatment and prevention of osteoporosis in postmenopausal women. PM: https://pdf.hres.ca/dpd_pm/00002184.PDF; date not captured; DIN 02279215; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1 INDICATIONS ACTONEL (risedronate sodium hemi-pentahydrate) is indicated for:  the treatment and prevention of osteoporosis in postmenopausal women1  the treatment of osteoporosis in men, to improve bone mineral density  the treatment and prevention of glucocorticoid-induced osteoporosis in men and women1  Paget's disease of bone1 ACTONEL DR (risedronate sodium hemi-pentahydrate) in indicated for:  The treatment of osteoporosis in postmenopausal women 1Although risedronate tablets 5 mg and 30 mg are available in the marketplace, ACTONEL is no longer marketed in the 5 mg and 30 mg strengths. It may be necessary to use alternate risedronate sodium products to achieve the appropriate dose. Postmenopausal Osteoporosis: In the treatment of osteoporosis in postmenopausal women at risk of fracture, ACTONEL and ACTONEL DR prevent vertebral and nonvertebral osteoporosis-related (fragility) fractures and increase bone mineral density (BMD) at all measured skeletal sites of clinical importance for osteoporotic fractures, including spine, hip, and wrist. Osteoporosis may be confirmed by the presence or history of osteoporotic fra… https://pdf.hres.ca/dpd_pm/00068139.PDF PM date: NOV 3, 2022 Source product: ACTONEL; DIN 02246896; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Teva-Risedronate · DIN 02298384 Shortage status: discontinued (2025-04-07, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02298384

Check this DIN again

Auro-Risedronate · DIN 02442760 Shortage status: active shortage (reported 2019-03-05, last updated 2019-03-06) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02442760

Check this DIN again

Jamp-Risedronate · DIN 02368552 Shortage status: active shortage (reported 2019-11-01, estimated to end 2022-12-30, last updated 2021-04-07) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02368552

Check this DIN again

Actonel · DIN 02242518 Shortage status: active shortage (reported not recorded, last updated 2018-12-20) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242518

Check this DIN again

Actonel · DIN 02239146 Shortage status: discontinued (2017-01-20, reported by ALLERGAN PHARMA CO.); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02239146

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)

Other review policies

For Actonel: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026